As of 2026-03-25, the Relative Valuation of BridgeBio Pharma Inc (BBIO) is (38.89) USD. This relative valuation is based on P/E multiples. With the latest stock price at 68.53 USD, the upside of BridgeBio Pharma Inc based on Relative Valuation is -156.7%.
The range of the Relative Valuation is (34.03) - (41.28) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 11.0x | 9.1x |
| Forward P/E multiples | 9.1x - 18.0x | 11.6x |
| Fair Price | (34.03) - (41.28) | (38.89) |
| Upside | -149.7% - -160.2% | -156.7% |
| Date | P/E |
| 2026-03-24 | -18.33 |
| 2026-03-23 | -18.61 |
| 2026-03-20 | -18.33 |
| 2026-03-19 | -18.74 |
| 2026-03-18 | -18.75 |
| 2026-03-17 | -18.97 |
| 2026-03-16 | -18.99 |
| 2026-03-13 | -18.56 |
| 2026-03-12 | -18.18 |
| 2026-03-11 | -19.09 |
| 2026-03-10 | -19.87 |
| 2026-03-09 | -17.55 |
| 2026-03-06 | -17.48 |
| 2026-03-05 | -17.70 |
| 2026-03-04 | -17.79 |
| 2026-03-03 | -17.26 |
| 2026-03-02 | -17.52 |
| 2026-02-27 | -17.78 |
| 2026-02-26 | -18.08 |
| 2026-02-25 | -17.79 |
| 2026-02-24 | -18.27 |
| 2026-02-23 | -18.16 |
| 2026-02-20 | -18.22 |
| 2026-02-19 | -18.91 |
| 2026-02-18 | -19.77 |
| 2026-02-17 | -20.28 |
| 2026-02-13 | -20.12 |
| 2026-02-12 | -20.34 |
| 2026-02-11 | -19.61 |
| 2026-02-10 | -19.38 |
| 2026-02-09 | -19.33 |
| 2026-02-06 | -18.20 |
| 2026-02-05 | -17.04 |
| 2026-02-04 | -20.11 |
| 2026-02-03 | -20.91 |
| 2026-02-02 | -20.92 |
| 2026-01-30 | -20.66 |
| 2026-01-29 | -21.15 |
| 2026-01-28 | -20.72 |
| 2026-01-27 | -20.82 |
| 2026-01-26 | -20.81 |
| 2026-01-23 | -20.82 |
| 2026-01-22 | -21.37 |
| 2026-01-21 | -20.90 |
| 2026-01-20 | -20.64 |
| 2026-01-16 | -20.39 |
| 2026-01-15 | -20.39 |
| 2026-01-14 | -20.83 |
| 2026-01-13 | -21.16 |
| 2026-01-12 | -20.55 |